BsAbs are artificially designed molecules, which enable to simultaneously recognize two or more different antigens. Bispecific antibody design includes Target Based BsAb Design, MOA Based BsAb Design, Application Based BsAb Design. https://www.creative-biolabs.com/bsab/bsab-design.htm

1. Bispecific AntibodyBispecific Antibody
DesignDesign
Ref: https://www.creative-biolabs.com/bsab/bsab-design.htm

2. Contents
01 Introduction
02 Target Based BsAb
Design
03 MOA Based BsAb Design
04 Application Based BsAb Design

3. Introduction
BsAbs are artificially designed molecules, which enable to simultaneously
recognize two or more different antigens.
PART 01

4. PART 01
Introduction
BsAbs have become a crucial therapeutic option for patients with cancer,
inflammatory, autoimmune, and other diseases. The dual specificity of BsAbs gives
them a variety of applications, such as blocking two different signaling pathways,
redirecting immune cells to tumor cells, and dual targeting of different disease
mediators. Nowadays, more than 60 different BsAb formats exist, some of which are
being developed in the clinical pipeline.

5. Target Based BsAb Design
BsAbs are artificially designed molecules, which enable to simultaneously
recognize two or more different antigens.
PART 02

6. Target Based BsAb Design
02
04
03
01
01 、 BsAbs Targeting Different Epitopes
BsAbs can target two of such mediators at the same time, block multiple
pathological factors/ pathways, and improve therapeutic efficacy.
03 、 BsAbs Targeting Different Receptors
Depending on the specific location on the membrane, receptors can be classified into
three groups: cell surface receptors, cytoplasmic receptors, and nuclear receptors.
02 、 BsAbs Targeting Different Ligands
DVD-IgG, scFv-IgG, diabody, scFv-HSA fusion protein, and DART are some formats of
BsAbs that have been developed to target soluble ligands in signaling pathways.
04 、 BsAbs Targeting Immune Cells
Specific BsAbs can retarget immune cells to tumor cells and induce anti-tumor
immune responses, including T-cell mediated cell death, antibody-dependent
cellular cytotoxicity (ADCC) and/or phagocytosis.

7. MOA Based BsAb Design
Therapeutic BsAbs mainly function through four MOAs: immune cell recruitment,
signaling interference, forced protein associations, and payload delivery.
PART 03

8. MOA Based BsAb Design
01 02
03 04
02 、 Receptor Signaling Interference
A number of BsAbs have been designed to block ligand-receptor
interactions involved in cell proliferation, cell motility, and angiogenic
development, to control cancer progression. Therapeutic BsAbs have also
been applied to ophthalmology, immunology, and pulmonary/ respiratory
diseases.
01 、 Immune Cell Recruitment
Once immune cells are redirected to and make contacts with tumor
cells, subsequent anti-tumor reactions (e.g., the release of cytokines
and phagocytosis) eventually kill tumor cells. Therefore immune cell
recruitment is a popular MOA of therapeutic BsAbs for cancer
treatment.
04 、 Payload Delivery
BsAb-mediated payload delivery is widely used in radio-
immunodetection and radio-immunotherapy, which greatly improves
the specificity and sensitivity of imaging and therapeutic effects in
cancer treatment
03 、 Forced Protein Associations
One well-known example in this category is the BsAb RG6013, anti-
FIXa/FX. This KIH-common light chain IgG derivative is used in
patients with the bleeding disorder hemophilia A.

9. Application Based BsAb Design
Oncology, immunology, hematology, ophthalmology, osteology, pulmonary and
respiratory diseases, pretargeting systems, diagnostics, and gene therapy.
PART 04

10. Application Based BsAb Design
01 、 Oncology
BsAbs are engineered to interfere with signaling pathways involved
in tumor development, or redirect cytotoxic immune cells such as T
cells and NK cells to kill tumors.
03 、 Hematology
Including treatment of different kinds of blood cancers such as acute
myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B cell
ALL), chronic lymphocytic leukemia (CLL), and hemophilia.
05 、 Osteology
BsAbs targeting RANKL itself and the RANKL/RNAK signaling
pathway have been designed and generated to treat these malignant
diseases.
02 、 Immunology
BsAbs are capable of receptor signaling interference
and can be applied to immunology.
04 、 Ophthalmology
BsAbs are great drug formats for next-generation
therapeutics in the pharmaceutical industry for ocular
disease treatment.
06 、 Pulmonary and Respiratory Diseases
BsAbs can bind ligands or receptors and block unwanted signaling
pathways and be useful in treating pulmonary and respiratory diseases.
01 02
03 04
05 06

11. Thanks